期刊
BREAST CANCER RESEARCH AND TREATMENT
卷 198, 期 2, 页码 361-368出版社
SPRINGER
DOI: 10.1007/s10549-023-06871-w
关键词
Breast cancer; Estrogen therapy; Survivors; Endocrine therapy
类别
This study investigates the impact of estrogen therapy on breast cancer mortality risk in women receiving adjuvant endocrine treatment. The results suggest that concurrent use of estrogen therapy with endocrine treatment, either in the short term or long term, does not significantly increase the risk of breast cancer mortality.
PurposeThe safety of local estrogen therapy in patients on adjuvant endocrine treatment is questioned, but evidence on the issue is scarce. This nested case-control registry-based study aimed to investigate whether estrogen therapy affects breast cancer mortality risk in women on adjuvant endocrine treatment.MethodsIn a cohort of 15,198 women diagnosed with early hormone receptor (HR)-positive breast cancer and adjuvant endocrine treatment, 1262 women died due to breast cancer and were identified as cases. Each case was matched with 10 controls. Exposure to estrogen therapy with concurrent use of aromatase inhibitors (AIs), tamoxifen, or both sequentially, was compared between cases and controls.ResultsNo statistically significant difference in breast cancer mortality risk was seen in patients with exposure to estrogen therapy concurrent to endocrine treatment, neither in short-term or in long-term estrogen therapy use.ConclusionsThe study strengthens current evidence on local estrogen therapy use in breast cancer survivors, showing no increased risk for breast cancer mortality in patients on adjuvant AIs or tamoxifen.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据